Physician’s Profile

Todd L. Rosenblat, MD

Department of Medicine
Division of Hematology/Oncology
Introduction:

Dr. Rosenblat is an assistant professor of medicine at Columbia University Medical Center, College of Physicians and Surgeons. He is a hematologist/oncologist with expertise in the diagnosis and treatment of acute and chronic leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome.

His research focuses on development of new and more effective treatments for patients with acute myeloid leukemia. This includes the development of novel drugs and drug combinations, as well as immunotherapy for myeloid leukemias. He received his MD degree from Stony Brook University and completed his fellowship in medical oncology/hematology at Memorial Sloan-Kettering Cancer Center.

Board Certificates
Medical Oncology
Hematology
Internal Medicine
Areas of Expertise:
  • Myelodysplastic Syndrome
  • Leukemia
  • Cancer Care
  • Acute Leukemia
  • Acute Lymphocytic Leukemia
  • Acute Myelogenous Leukemia
  • Aplastic Anemia
  • Chronic Leukemia
  • Chronic Lymphoid Leukemia
  • Chronic Myelogenous Leukemia
  • Essential Thrombocythemia
  • Hairy Cell Leukemia
  • Hematologic Malignancy
  • Large Granular Lymphocytic Leukemia
  • Lymphoblastic Leukemia
  • Myelofibrosis
  • Myeloproliferative Disease
  • Polycythemia Vera
  • Waldenstrom's Macroglobulinemia
Publications:
Renier J. Brentjens, Marco L. Davila, Isabelle Riviere, Jae Park, Xiuyan Wang, Lindsay G. Cowell, Shirley Bartido, Jolanta Stefanski, Clare Taylor, Malgorzata Olszewska, Oriana Borquez-Ojeda, Jinrong Qu, Teresa Wasielewska, Qing He, Yvette Bernal, Ivelise V. Rijo, Cyrus Hedvat, Rachel Kobos, Kevin Curran, Peter Steinherz, Joseph Jurcic, Todd Rosenblat, Peter Maslak, Mark Frattini and Michel Sadelain.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. Sci Transl Med 2013: 177(5);177ra38  Altman JK, Rademaker A, Cull E, Weitner BB, Ofran Y, Rosenblat TL, Haidau A, Park JH, Ram SL, Orsini JM Jr, Sandhu S, Catchatourian R, Trifilio SM, Adel NG, Frankfurt O, Stein EM, Mallios G, Deblasio T, Jurcic JG, Nimer S, Peterson LC,Kwaan HC, Rowe JM, Douer D, Tallman MS. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res. 2013;37(9):1004-9 Roboz GJ, Rosenblat T, Arellano M, Gobbi M, Altman JK, Montesinos P, O'Connell C, Solomon SR, Pigneux A, Vey N, Hills R, Jacobsen TF, Gianella-Borradori A, Foss O, Vetrhusand S, Giles FJ.  International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia. J Clin Oncol. 2014 May 19